Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer

American Journal of Epidemiology

Volumn 144, Issue 2, 1996, Pages 142-149

  Aromas, Arpo ^a,b   Kosunen, Timo U ^c   Knekt, Paul ^a,b   Maatela, Jouni ^b   Teppo, Lyly ^d   Heinonen, Olli P ^c   Härkönen, Matti ^c   Hakama, Matti K ^e  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b SOCIAL INSURANCE INSTITUTION   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Helicobacter pylori; IgA; IgG; longitudinal studies; pepsinogen; stomach neoplasms

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; PEPSINOGEN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FINLAND; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; STOMACH CANCER;

EID: 0030036091     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008901     Document Type: Article

References (38)

1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97.
2. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev 1986;8:1-27.
3. Pukkala E, Gustavsson N, Teppo L. Atlas of cancer incidence in Finland 1953-1982. Helsinki: Cancer Society of Finland, 1987:20. (CSF publication no. 37).
4. Marshall BJ, Armstrong JA, McGechie DB, et al. Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust 1985;142:436-43.
5. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990;161:626-33.
6. Siurala M, Isokoski M, Vans K, et al. Prevalence of gastritis in a rural population. Bioptic study of subjects selected at random. Scand J Gastroenterol 1968;3:211-23.
7. Walker IR, Strickland RG, Ungar B, et al. Simple atrophic gastritis and gastric carcinoma. Gut 1971;12:906-11.
8. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990;50:4737-40.
9. Nomura A, Stemmermann GN, Chyou P-H, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120:977-80.
10. Talley NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991;83:1734-9.
11. Sipponen P, Kosunen TU, Valle J, et al. Helicobacter pylori and chronic gastritis in gastric cancer. J Clin Pathol 1992;45: 319-23.
12. Kuipers EJ, Pena AS, van Kamp G, et al. Seroconversion for Helicobacter pylori. Lancet 1993;342:328-31.
13. Forman D, Sitas F, Newell DG, et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 1990;46:608-11.
14. The Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-62.
15. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991;302: 1302-5.
16. Nomura A, Stemmermann GN, Chyou P-H, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;321:1132-6.
17. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
18. Strauss RM, Wang TC, Kelsey PB, et al. Association of Helicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am J Med 1990;89: 464-9.
19. Karnes WE, Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991;101:167-74.
20. Crabtree JE, Wyatt JI, Sobala GM, et al. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut 1993;34:1339-43.
21. Kosunen TU, Seppälä K, Sarna S, et al. Diagnostic value of decreasing IgG, IgA, and IgM antibody titers after eradication of Helicobacter pylori. Lancet 1992;339:893-5.
22. Tamm A, Villako K, Härkönen M, et al. Serum pepsinogen I and the state of gastric mucosa in an Estonian population sample. Scand J Gastroenterol 1984;19:1091-4.
23. Farinati F, di Mario F, Plebani M, et al. Pepsinogen A/pepsinogen C or pepsinogen A multiplied by gastrin in the diagnosis of gastric cancer? Ital J Gastroenterol 1991;223: 194-6.
24. Nomura AMY, Stemmermann GN, Samloff IM. Serum pepsinogen I as predictor of stomach cancer. Ann Intern Med 1980;93:537-40.
25. Parsonnet J, Samloff M, Nelson LM, et al. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prevention 1993;2:461-6.
26. Aromaa A. Epidemiology and public health impact of high blood pressure in Finland. (In Finnish with an English summary). Helsinki: Social Insurance Institution, 1981. (AL:17).
27. Knekt P, Aromaa A, Maatela J, et al. Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 1988;127:28-41.
28. Teppo L, Pukkala E, Hakama M, et al. Way of life and cancer incidence in Finland. A municipality based ecological analysis. Scand J Soc Med 1980;8(suppl 19):1-84.
29. Breslow NE, Day NE, eds. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. Lyon: International Agency for Research on Cancer, 1980. (IARC scientific publication no. 32).
30. Malaty HM, Engstrand L, Pedersen NL, et al. Helicobacter pylori infection: genetic and environmental influences. A study of twins. Arch Intern Med 1994;120:982-6.
31. Banatvala N, Mayo K, Megraud F, et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168:219-21.
32. Brenes F, Ruiz P, Correa P, et al. Helicobacter pylori causes hyperproliferation of the gastric epithelium: pre- and post-eradication indices of proliferating cell nuclear antigen. Am J Gastroenterol 1993;88:1870-5.
33. Sobala GM, Crabtree JE, Dixon MF, et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentration. Gut 1991;32:1415-18.
34. Figura N, Guglielmetti P, Rossolini A, et al. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol 1989;27:225-6.
35. Rautelin H, Blomberg B, Fredlund H, et al. Incidence of Helicobacter pylori strains activating neutrophils in patients with peptic ulcer disease. Gut 1993;34:599-604.
36. Hirai M, Azuma T, Ito S, et al. High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric carcinoma patients. Int J Cancer 1994;56:56-80.
37. Blaser MJ, Pérez-Pérez GI, Kleanthouse H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with increased risk of developing adenocarcinoma of the stomach among Japanese-American men in Hawaii. (Abstract 283). Presented at the VIIth Workshop on Gastroduodenal Pathology and Helicobacter pylori, Houston, Texas, September-October 1994.
38. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.